Zambia Leads Africa with Launch of Injectable PrEP for HIV Prevention
Zambia has become the first African country to introduce injectable Pre-Exposure Prophylaxis (PrEP) as part of its arsenal against HIV/AIDS.
The announcement was made by the Minister of Health, Sylvia Masebo, during a launch event held in Chibombo.
The newly introduced Long-Acting Injectable Cabotegravir (CAB-LA) offers a revolutionary two-month prevention window from the last time of injection, marking a significant advancement in HIV prevention strategies.
Minister Masebo emphasized that this breakthrough would play a crucial role in curbing the high rates of HIV infections, particularly among the youth population.
Under the initial phase of implementation, the injectable PrEP, also known as CAB-LA, will be available at select healthcare facilities including University Teaching Hospital, Matero Main Health Centre, Mazabuka Dreams Centres, Kitwe Hub, Mwanjuni Health Centre, and Nakonde Urban Clinic.
Minister Masebo urged individuals who are HIV negative to take advantage of this new preventive measure by visiting the designated facilities to receive the injectable PrEP. By doing so, they can significantly reduce their risk of contracting HIV.
Currently, Zambia has received an initial shipment of 15,000 vials of CAB-LA, with plans through the Zambia Medicines and Medical Supplies Agency (ZAMMSA) to procure an additional 37,000 vials later in the year.
This proactive approach underscores Zambia’s commitment to combating the HIV epidemic and safeguarding the health of its citizens.
The introduction of injectable PrEP represents a significant milestone not only for Zambia but for the entire African continent in the fight against HIV/AIDS.
With this innovative prevention tool now available, Zambia sets a precedent for other nations to follow in adopting effective strategies to reduce HIV transmission and improve public health outcomes.
